文献速递眼底病与葡萄膜炎

衣康酸通过DNAJA1/CDC45轴调节Teff/Treg细胞失衡改善实验性自身免疫性葡萄膜炎

Itaconate Ameliorates Experimental Autoimmune Uveitis by Modulating Teff/Treg Cell Imbalance Via the DNAJA1/CDC45 Axis.
PubMed 文献 · Invest Ophthalmol Vis Sci · 2024-01-01

该研究在小鼠实验性自身免疫性葡萄膜炎(EAU)模型中探究衣康酸(ITA)的治疗作用及机制,采用单细胞RNA测序和流式细胞术分析。结果显示ITA减轻眼部炎症、逆转Th17相关致病分化及活性氧(ROS)和氧化应激通路,并通过抑制DNAJA1/CDC45表达破坏CD4+ T细胞致病性分裂周期、减少增殖;激活热休克蛋白(HSP)可逆转ITA的抗炎效果。ITA还减少葡萄膜炎患者CD4+ T细胞扩增。

要点

  • ITA减轻EAU小鼠眼部炎症并逆转Th17相关致病分化及ROS/氧化应激通路。
  • ITA通过抑制DNAJA1/CDC45破坏CD4+ T细胞致病性分裂周期、减少增殖。
  • 激活HSP可逆转ITA在EAU小鼠中的抗炎效果,DNAJA1是HSP中变化最显著者。

核心结论

  • ITA在EAU中通过调节DNAJA1/CDC45轴影响Teff/Treg细胞失衡而发挥治疗作用。
  • DNAJA1是葡萄膜炎靶向治疗的有前景候选靶点。

研究设计与样本

  • 建立小鼠EAU动物模型,对ITA治疗小鼠构建免疫图谱。
  • 采用单细胞RNA测序和流式细胞术探究ITA的治疗机制。

主要发现

  • ITA减轻EAU相关眼部炎症,并逆转EAU诱导的Th17相关致病分化以及ROS和氧化应激通路。
  • ITA干预后T细胞亚群中下调的差异表达基因主要集中于HSP家族。
  • 激活HSP可逆转ITA在EAU小鼠中的抗炎效果。
  • ITA降低CD4+ T细胞中ROS水平和HSP表达,其中DNAJA1在HSP中变化最显著。
  • ITA抑制DNAJA1/CDC45表达,破坏CD4+ T细胞的致病性分裂周期并减少其增殖;抑制DNAJA1也有望调节Th17/Treg失衡。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The aim of this study was to elucidate the effect of itaconate (ITA) on experimental autoimmune uveitis (EAU), to explore its potential mechanism, and to identify potential therapeutic targets. METHODS: We established an animal model of EAU by constructing an immune map of mice treated with ITA and exploring the therapeutic mechanism of ITA by single-cell RNA sequencing and flow cytometry. RESULTS: ITA mitigated ocular inflammation associated with EAU and reversed the pathogenic differentiation linked to Th17 induction by EAU, along with the reactive oxygen species (ROS) and oxidative stress pathways. Subsequent to ITA intervention, the downregulated differentially expressed genes in the T-cell subset primarily centered around the heat shock protein (HSP) family. Activation of HSPs reversed the anti-inflammatory effects of ITA in EAU mice. ITA decreased ROS levels and HSP expression in CD4+ T cells, with DnaJ heat shock protein family (HSP40) member A1 (DNAJA1) exhibiting the most notable alterations among the HSPs. ITA suppressed the expression of DNAJA1/cell division cycle protein 45 (CDC45), thereby disrupting the pathogenic division cycle of CD4+ T cells and reducing their proliferation. Inhibiting DNAJA1 also held promise for modulating the Th17/Treg imbalance. Notably, ITA curtailed the expansion of CD4+ T cells in uveitis patients. CONCLUSIONS: Our research delved into the potential therapeutic mechanisms underlying ITA therapy in EAU, offering fresh perspectives on its utility in the treatment of autoimmune conditions. DNAJA1 emerges as a promising candidate for targeted therapeutic interventions in uveitis.

来源:Invest Ophthalmol Vis Sci,查看原文。版权归原作者所有。

引用

  1. Jiang Q, Li Z, Huang Y, et al. Itaconate Ameliorates Experimental Autoimmune Uveitis by Modulating Teff/Treg Cell Imbalance Via the DNAJA1/CDC45 Axis. Invest Ophthalmol Vis Sci. 2024. PMID: 39661355. doi:10.1167/iovs.65.14.23

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。